These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3921593)

  • 21. Cortisol secretion following nomifensine administration in normal subjects.
    Alagna S; Masala A
    Biomedicine; 1979 Nov; 31(7):189-91. PubMed ID: 526541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum thyrotropin and prolactin in the syndrome of generalized resistance to thyroid hormone: responses to thyrotropin-releasing hormone stimulation and short term triiodothyronine suppression.
    Sarne DH; Sobieszczyk S; Ain KB; Refetoff S
    J Clin Endocrinol Metab; 1990 May; 70(5):1305-11. PubMed ID: 2110573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship of changes in serum estradiol and progesterone during the menstrual cycle to the thyrotropin and prolactin responses to thyrotropin-releasing hormone.
    Sawin CT; Hershman JM; Boyd AE; Longcope C; Bacharach P
    J Clin Endocrinol Metab; 1978 Dec; 47(6):1296-302. PubMed ID: 122427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolactin changes after administration of agonist and antagonist dopaminergic drugs in puerperal women.
    Petraglia F; De Leo V; Sardelli S; Mazzullo G; Gioffrè WR; Genazzani AR; D'Antona N
    Gynecol Obstet Invest; 1987; 23(2):103-9. PubMed ID: 3583091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nomifensine: diagnostic test in hyperprolactinemic states.
    Müller EE; Genazzani AR; Murru S
    J Clin Endocrinol Metab; 1978 Dec; 47(6):1352-7. PubMed ID: 263356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Prl secretion in elderly subjects.
    Rolandi E; Magnani G; Sannia A; Barreca T
    Acta Endocrinol (Copenh); 1982 Jul; 100(3):351-7. PubMed ID: 6810616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolactin secretion after surgery or bromocriptine treatment of prolactinoma.
    De Leo V; Petraglia F; Sardelli S; Danero S; Genazzani AR; D'Antona N
    Obstet Gynecol; 1987 Jan; 69(1):99-103. PubMed ID: 3099236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-induced alterations of the hypothalamus-hypophysis axis.
    Mazzi C; Riva LP; Morandi G; Mainini E; Martinelli I; Bertaccini G
    Acta Psychiatr Belg; 1980; 80(5):619-37. PubMed ID: 7234453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased prolactin response to thyrotropin-releasing hormone in primary ovarian failure.
    Hochner-Celnikier D; Zylber-Haran E; Shilo S; Palti Z; Spitz IM
    Obstet Gynecol; 1982 Mar; 59(3):280-4. PubMed ID: 6804899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperprolactinemia in hepatic encephalopathy may result from impaired central dopaminergic neurotransmission.
    Corenblum B; Shaffer EA
    Horm Metab Res; 1989 Dec; 21(12):675-7. PubMed ID: 2559014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolactin response to N3im-methyl-thyrotropin releasing hormone in euthyroid subjects.
    Sowers JR; Hershman JM; Carlson HE; Pekary E; Nair MG; Baugh CM
    J Clin Endocrinol Metab; 1976 Oct; 43(4):749-55. PubMed ID: 824297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolactin dynamics in normoprolactinemic primary empty sella: correlation with intracranial pressure.
    Barbarino A; De Marinis L; Mancini A; D'Amico C; Sambo P; Passeri M; Anile C; Maira G
    Horm Res; 1987; 27(3):141-51. PubMed ID: 3121488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma growth hormone and prolactin response to thyrotropin releasing hormone, L-dopa and luteinizing hormone-releasing hormone in alcoholic patients with liver cirrhosis.
    Zanoboni A; Zanoboni-Muciaccia W; Bonfanti M; Gattei G; Zecca L
    Farmaco Prat; 1980 Sep; 35(9):455-65. PubMed ID: 6778710
    [No Abstract]   [Full Text] [Related]  

  • 34. Evidence of abnormal dopaminergic control of prolactin in patients with hypothalamic and pituitary tumors.
    Cabranes JA; Almoguera I; del Olmo J; Prensa A; Pablos I; Charro AL
    J Med; 1986; 17(1):25-39. PubMed ID: 3035040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peripheral elimination of growth hormone in chronic liver disease.
    Bauer AG; Lamberts SW; Wilson JH
    Horm Res; 1982; 16(2):126-32. PubMed ID: 6809553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas.
    Arafah BM; Nekl KE; Gold RS; Selman WR
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3507-12. PubMed ID: 8530591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth hormone and prolactin responses to thyrotropin-releasing hormone in patients with severe liver disease.
    Panerai AE; Salerno F; Manneschi M; Cocchi D; Müller EE
    J Clin Endocrinol Metab; 1977 Jul; 45(1):134-40. PubMed ID: 406272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pituitary hormone circadian rhythm alterations in cirrhosis patients with subclinical hepatic encephalopathy.
    Velissaris D; Karanikolas M; Kalogeropoulos A; Solomou E; Polychronopoulos P; Thomopoulos K; Labropoulou-Karatza C
    World J Gastroenterol; 2008 Jul; 14(26):4190-5. PubMed ID: 18636665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Basal serum prolactin in liver cirrhosis and its clinical significance].
    Dang ZD; Tao JY; Zhu LF
    Zhonghua Nei Ke Za Zhi; 1985 Mar; 24(3):153-4, 190. PubMed ID: 4006606
    [No Abstract]   [Full Text] [Related]  

  • 40. Failure of nomifensine administration to discriminate between tumorous and nontumorous hyperprolactinemia.
    Ferrari C; Crosignani PG; Caldara R; Picciotti MC; Malinverni A; Barattini B; Rampini P; Telloli P
    J Clin Endocrinol Metab; 1980 Jan; 50(1):23-6. PubMed ID: 7188615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.